

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LUPIN LTD. and LUPIN PHARMACEUTICALS INC.  
Petitioners

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and  
BAUSCH & LOMB PHARMA HOLDINGS CORP.  
Patent Owner

---

IPR2015-01097 (US Patent No. 8,754,131)  
IPR2015-01099 (US Patent No. 8,669,290)  
IPR2015-01100 (US Patent No. 8,927,606)  
IPR2015-01105 (US Patent No. 8,871,813)<sup>1</sup>

---

**PETITIONERS' UPDATED EXHIBIT LIST**

---

<sup>1</sup> The word-for-word identical paper is filed in each proceeding identified in the heading. IPR2016-00089 has been joined with IPR2015-01097; IPR2016-00091 has been joined with IPR2015-01100; and IPR2016-00090 has been joined with IPR2015-01105. Each of these joined proceedings includes Petitioners InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. (collectively, "InnoPharma") in addition to the parties identified above.

## I. INTRODUCTION

Pursuant to 37 C.F.R. § 42.63(e), Petitioners Lupin Ltd. And Lupin Pharmaceuticals Inc. (collectively “Petitioners”) hereby submit a current listing of Petitioner Exhibits to counsel for Patent Owner Senju Pharmaceutical Co., Ltd., Bauch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp. (collectively “Patent Owner”).

<b><i>Exhibit #</i></b>	<b><i>Description</i></b>
<b>1001</b>	Sawa et al., U.S. Patent No. 8,669,290, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued March 11, 2014.
<b>1002</b>	Sawa et al., U.S. Patent No. 8,754,131, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued June 17, 2014.
<b>1003</b>	Sawa et al., U.S. Patent No. 8,871,813, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued October 28, 2014.
<b>1004</b>	Sawa et al., U.S. Patent No. 8,927,606, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued January 6, 2015.
<b>1005</b>	Declaration of Dr. Jayne Lawrence
<b>1006</b>	Hara, Y., "Bromfenac sodium hydrate," <i>Clinics &amp; Drug Therapy</i> 19:1014-1015 (2002).
<b>1007</b>	Yanni et al., U.S. Patent No. 5,475,034, "Topically Administrable Compositions Containing 3-Benzoylphenylacetic Acid Derivatives for Treatment of Ophthalmic Inflammatory Disorders," issued December 12, 1995.
<b>1008</b>	FDA Approved “Xibrom™ (bromfenac ophthalmic solution, 0.09%) Product Label,” ISTA Pharmaceuticals, Inc.

<b>1009</b>	FDA Approved "BROMDAY™ (bromfenac ophthalmic solution, 0.09%) Product Label," U.S. Approval March 24, 2005, ISTA Pharmaceuticals, Inc.
<b>1010</b>	Ogawa et al., U.S. Patent No. 4,910,225, "Locally Administrable Therapeutic Composition for Inflammatory Disease," issued March 20, 1990.
<b>1011</b>	Sallmann et al., U.S. Patent No. 6,107,343, "Ophthalmic And Aural Compositions Containing Diclofenac Potassium," issued August 22, 2000.
<b>1012</b>	Desai et al., U.S. Patent No. 5,603,929, "Preserved Ophthalmic Drug Compositions Containing Polymeric Quaternary Ammonium Compounds," issued February 18, 1997.
<b>1013</b>	Desai et al., U.S. Patent No. 5,558,876, "Topical Ophthalmic Acidic Drug Formulations," issued September 24, 1996.
<b>1014</b>	Fu et al., European Patent Application No. 88114804.3, "Preservative System for Ophthalmic Formulations," published as EP 0 306 984 A1 on March 15, 1989.
<b>1015</b>	Schott, H., "Comparing the Surface Chemical Properties and the Effect of Salts on the Cloud Point of a Conventional Nonionic Surfactant, Octoxynol 9 (Triton X-100), and of Its Oligomer, Tyloxapol (Triton WR-1339)," <i>Journal of Colloid and Interface Science</i> 205: 496-502 (1998).
<b>1016</b>	"Acular®" and "Azopt™," <i>Physician's Desk Reference</i> , 54:486-487, and 491-492 (2000).
<b>1017</b>	Doughty, M., "Medicines Update for optical practitioners - Part 11," <i>Optician</i> , 5853:223 (2002).
<b>1018</b>	FDA approved "ALREX™ (loteprednol etabonate ophthalmic suspension) 0.2% Product Label," U.S. Approval: 1998, Bausch & Lomb Pharmaceuticals.
<b>1019</b>	FDA approved "LOTEMAX™ (loteprednol etabonate ophthalmic suspension) 0.5% Product Label," U.S. Approval: 1998, Bausch & Lomb Pharmaceuticals.
<b>1020</b>	"Alomide®", <i>Physician's Desk Reference</i> , 50:469 (1996).

<b>1021</b>	Sallmann et al., U.S. Patent No. 5,891,913, "Ophthalmic and Aural Compositions Containing Diclofenac Potassium," issued April 6, 1999.
<b>1022</b>	Yasueda et al., U.S. Patent No. 6,274,609, "Aqueous Liquid Pharmaceutical Composition Containing as Main Component Benzopyran Derivative," issued August 14, 2001.
<b>1023</b>	Claim Chart, U.S. Patent No. 8,669,290.
<b>1024</b>	Claim Chart, U.S. Patent No. 8,754,131.
<b>1025</b>	Claim Chart, U.S. Patent No. 8,871,813.
<b>1026</b>	Claim Chart, U.S. Patent No. 8,927,606.
<b>1027</b>	Wong, M., International Patent Application No. PCT/US94/00188, "Ophthalmic Compositions Comprising Benzylaurilydimethylammonium Chloride," published July 21, 1994 as WO 94/15597.
<b>1028</b>	Regev et al., "Aggregation Behavior of Tyloxapol, a Nonionic Surfactant Oligomer, in Aqueous Solution," <i>Journal of Colloid and Interface Science</i> , 210: 8-17 (1999).
<b>1029</b>	"TOBRADEX®" Physician's Desk Reference 54: 490-491 (2000).
<b>1030</b>	Orange Book Listing, Nevanac: <a href="http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No= 021862&amp;TABLE1=OB_Rx">http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No= 021862&amp;TABLE1=OB_Rx</a>
<b>1031</b>	Nevanac Label: <a href="http://ecatalog.alcon.com/PI/Nevanac_us_en.pdf">http://ecatalog.alcon.com/PI/Nevanac_us_en.pdf</a>
<b>1032</b>	Wong, W., U.S. Patent No. 7,834,059, "Topical Nepafenac Formulations," issued November 16, 2010.
<b>1033</b>	Gamache et al., International Patent No. PCT/US01/25319, "Method of Treating Neurodegenerative Disorders of the Retina and Optic Nerve Head," published February 21, 2002 as WO 02/13805.
<b>1034</b>	Gamache et al., U.S. Patent Application Publication No. 2002/0049255, "Method of Treating Neurodegenerative Disorders of the Retina and Optic Nerve Head," published April 25, 2002.
<b>1035</b>	Gamache et al., U.S. Patent No. 6,638,976, "Method of Treating Neurodegenerative Disorders of the Retina and Optic Nerve Head," issued October 28, 2003.

<b>1036</b>	Kapin et al., International Patent No. PCT/US01/25318, "Method for Treating Angiogenesis-Related Disorders Using Benzoyl Phenylacetic Acid," published February 21, 2002 as WO 2002/13804.
<b>1037</b>	Patani, G. and LaVoie, E., "Bioisosterism: A Rational Approach in Drug Design," <i>Chem. Rev.</i> 96: 3147-3176 (1996).
<b>1038</b>	Ostrovskii et al., "Acid-Base Properties of 5-Substituted Tetrazoles," <i>Chemistry of Heterocyclic Compounds</i> , 17:412-416 (1981).
<b>1039</b>	Bergamini et al., U.S. Patent No. 5,597,560, "Diclofenac And Tobramycin Formulations For Ophthalmic And Otis Topical Use," issued January 28, 1997.
<b>1040</b>	Ali et al., U.S. Patent No. 6,071,904, "Process for Manufacturing Ophthalmic Suspensions," issued June 6, 2000.
<b>1041</b>	Shupe, I., U.S. Patent No. 3,272,700, "Stabilized Aqueous Solution of Tetracine Salt," issued September 13, 1966.
<b>1042</b>	Guttman et al., "Solubilization of Anti-inflammatory Steroids by Aqueous Solutions of Triton-WR-1339," <i>Journal of Pharmaceutical Sciences</i> , 50: 305-307 (1961).
<b>1043</b>	U.S. Patent No. 8,129,431 (App. No. 10/525,006) - PAIR File History
<b>1044</b>	U.S. Patent No. 8,497,304 (App. No. 13/353,653) - PAIR File History
<b>1045</b>	U.S. Patent No. 8,669,290 (App. No. 13/687,242) - PAIR File History
<b>1046</b>	U.S. Patent No. 8,754,131 (App. No. 14/165,976) - PAIR File History
<b>1047</b>	U.S. Patent No. 8,871,813 (App. No. 14/261,720) - PAIR File History
<b>1048</b>	8,927,606 (App. No. 14493903) - PAIR File History
<b>1049</b>	FDA approved "PROLENSA® Product Label," approved April 5, 2013, Bausch & Lomb Inc.
<b>1050</b>	"Benzalkonium chloride," <i>Remington: The Science and Practice of Pharmacy</i> , A.R. Gennaro (Ed.), Mack, PA, 1995, p. 1264.
<b>1051</b>	"Tyloxapol," <i>Remington: The Science and Practice of Pharmacy</i> , A.R. Gennaro (Ed.), Mack, PA, 1995, pp. 1415-1416
<b>1052</b>	Senju Pharmaceutical Co., Ltd. Press Release, "The approval of BRONUCK® (bromfenac sodium hydrate ophthalmic solution) as an import drug in China."

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.